LetterThyroid-stimulating hormone (TSH) suppression in differentiated thyroid carcinoma: Combined treatment with triiodothyronine and thyroxine
References (7)
- et al.
Control of human thyroid follicular cell proliferation in suspension and monolayer culture
Mol Cell Endocrinol
(1987) - et al.
Delayed thyroid-stimulating hormone suppression by 1-thyroxine in the management of differentiated thyroid carcinoma
Eur J Cancer
(1993) - et al.
Treatment of thyroid cancer in 293 patients
Br J Surg
(1976)
There are more references available in the full text version of this article.
Cited by (2)
Natural history and clinical outcome of differentiated thyroid carcinoma: A retrospective analysis of 1503 patients treated at a single institution
2009, Annals of OncologyCitation Excerpt :All patients had stopped L-thyroxine and tri-iodothyronine 4–5 weeks and 15 days prior the first radioiodine procedure, respectively, in order to achieve a minimum of thyrotropin levels >30 mU/l on the day of 131I administration. Hormonal therapy was then replaced 24 h after radioiodine treatment in all patients [16]. A low-iodine diet was also requested during the 10 days before the radioiodine administration.
Epidemiology and therapy of thyroid cancer in childhood and adolescence
1997, Experimental and Clinical Endocrinology and Diabetes
Copyright © 1994 Published by Elsevier Ltd.